pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·Sep 14·1 min read
save

Sino Biological launches site-specific labeled proteins to aid cell surface research

Sep 14, 2026·read at BioSpace ↗Positive

Cell surface proteins play key roles in immune signaling, cell adhesion and tissue maintenance, making them important targets for therapies and diagnostics.

Researchers need reliable tools to detect and study these proteins, often relying on labeled recombinant versions for flow cytometry, cell sorting and binding assays.

Site-specific labeling attaches tags at defined amino‑acid positions, preserving the protein's natural shape and activity while providing consistent labeling ratios.

Sino Biological now offers a portfolio of such site‑specifically labeled recombinant proteins, designed to retain native conformation, high stability and functional activity for use in target validation and therapeutic discovery.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Unlocking cell surface protein research with site-specific labeling”

read at BioSpace ↗
1,206 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
ENHERTUGAZYVAOPDIVOOPDIVO QVANTIGavelumabaxicabtagene ciloleucelciltacabtagene autoleuceldurvalumabidecabtagene vicleucelisatuximablisocabtagene maraleucelnivolumabobinutuzumabtrastuzumab deruxtecan
topics
Oncology12Monoclonal Antibody11Immunology9CD198CAR-T3Bispecific Antibody2HER22ApprovalBCMACD38Diagnostics CompanyMultiple MyelomaPD-1

related stories

  • Sep 3AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialFierce Biotech
  • Aug 3Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaFierce Biotech
  • Jul 27Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleBioSpace
  • May 10Five Under 5: Top Oncology Videos for the Week of 5/3onclive
  • May 8Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanomaonclive